Compare AMC ENTERTAINMENT HOLDINGS, INC. (AMC) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMC ENTERTAINMENT HOLDINGS, INC. vs Medpace Holdings Inc — how do they compare? AMC ENTERTAINMENT HOLDINGS, INC. trades at $1.83 (market cap $1.69B), while Medpace Holdings Inc trades at $535.07 (market cap $15.37B). The key difference: Medpace Holdings Inc is far larger — about 9.1× AMC ENTERTAINMENT HOLDINGS, INC.'s market cap, and AMC ENTERTAINMENT HOLDINGS, INC. pays a 0.11% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| AMC | MEDP | |
|---|---|---|
Market Cap | $1.69B | $15.37B |
Sector | Media | Technology |
52-Week High | $3.54 | $620.59 |
52-Week Low | $0.95 | $308.88 |
Enterprise Value | $9.28B | $14.84B |
Dividend Yield | 0.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMC trades at $1.89, down 0.53% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 EPS of -$0.36, missing expectations, while revenue trends show modest growth from $4.6B in 2024 to $4.85B in 2025. Recent news highlights box office recovery optimism and a $200 million stock offering that caused dilution concerns.
Outlook remains challenging with persistent net losses and high debt burden, though analyst consensus targets $1.90 with 32% buy ratings. Key risks include ongoing dilution from equity offerings, competitive pressures in entertainment, and the need for sustained box office recovery to improve cash flow and profitability.
MEDP trades at $538.23, up 0.51% with a bullish technical signal and strong fundamentals. The stock shows robust profitability with 17.19% net margins and 77.25% ROE, though valuations appear elevated with a P/E of 33.87. Recent earnings consistently beat expectations, and 2026 projections indicate revenue growth to $2.7B. Technical analysis shows support at $527 and resistance at $543, with the current price near pivot point $535.
MEDP presents growth potential from strong CRO demand and earnings momentum, but faces risks from class action lawsuits and elevated valuation multiples. Analyst consensus is cautious with 74% hold ratings and a $479 price target below current levels. The stock's outlook depends on maintaining backlog quality amid rising cancellations and AI investment delays.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMC ENTERTAINMENT HOLDINGS, INC.
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
